Skip to main content

Main menu

  • Home
  • About
    • About CBM
    • Editorial Board
    • Announcement
  • Articles
    • Ahead of print
    • Current Issue
    • Archive
    • Collections
    • Cover Story
  • For Authors
    • Instructions for Authors
    • Resources
    • Submit a Manuscript
  • For Reviewers
    • Become a Reviewer
    • Instructions for Reviewers
    • Resources
    • Outstanding Reviewer
  • Subscription
  • Alerts
    • Email Alerts
    • RSS Feeds
    • Table of Contents
  • Contact us
  • Other Publications
    • cbm

User menu

  • My alerts

Search

  • Advanced search
Cancer Biology & Medicine
  • Other Publications
    • cbm
  • My alerts
Cancer Biology & Medicine

Advanced Search

 

  • Home
  • About
    • About CBM
    • Editorial Board
    • Announcement
  • Articles
    • Ahead of print
    • Current Issue
    • Archive
    • Collections
    • Cover Story
  • For Authors
    • Instructions for Authors
    • Resources
    • Submit a Manuscript
  • For Reviewers
    • Become a Reviewer
    • Instructions for Reviewers
    • Resources
    • Outstanding Reviewer
  • Subscription
  • Alerts
    • Email Alerts
    • RSS Feeds
    • Table of Contents
  • Contact us
  • Follow cbm on Twitter
  • Visit cbm on Facebook
Research ArticleOriginal Article

Targeting FGFR in non-small cell lung cancer: implications from the landscape of clinically actionable aberrations of FGFR kinases

Zhen Zhou, Zichuan Liu, Qiuxiang Ou, Xue Wu, Xiaonan Wang, Yang Shao, Hongyan Liu and Yu Yang
Cancer Biology & Medicine May 2021, 18 (2) 490-501; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0120
Zhen Zhou
1Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai 200030, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zichuan Liu
2Section No. 2 Internal Medicine, Cancer Center of Guangzhou Medical University, Guangzhou 511436, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Qiuxiang Ou
3Translational Medicine Research Institute, Geneseeq Technology Inc., Toronto M5G1L7, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xue Wu
3Translational Medicine Research Institute, Geneseeq Technology Inc., Toronto M5G1L7, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiaonan Wang
4Nanjing Geneseeq Technology Inc., Nanjing 211500, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yang Shao
3Translational Medicine Research Institute, Geneseeq Technology Inc., Toronto M5G1L7, Canada
5School of Public Health, Nanjing Medical University, Nanjing 211166, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hongyan Liu
6Department of Respiratory Medicine, The Second Hospital of Anhui Medical University, Hefei 230031, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Hongyan Liu
  • For correspondence: yangyu13836125585{at}163.com hongyanliu03{at}126.com
Yu Yang
7Department of Oncology, The Second Affiliated Hospital of Harbin Medical University, Harbin Medical University, Harbin 150086, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Yu Yang
  • For correspondence: yangyu13836125585{at}163.com hongyanliu03{at}126.com
  • Article
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
Loading

References

  1. 1.↵
    1. Katoh M,
    2. Nakagama H.
    FGF receptors: cancer biology and therapeutics. Med Res Rev. 2014; 34: 280–300.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Presta M,
    2. Chiodelli P,
    3. Giacomini A,
    4. Rusnati M,
    5. Ronca R.
    Fibroblast growth factors (FGFS) in cancer: FGF traps as a new therapeutic approach. Pharmacol Ther. 2017; 179: 171–87.
    OpenUrl
  3. 3.↵
    1. Hubbard SR,
    2. Till JH.
    Protein tyrosine kinase structure and function. Annu Rev Biochem. 2000; 69: 373–98.
    OpenUrlCrossRefPubMedWeb of Science
  4. 4.↵
    1. Haugsten EM,
    2. Wiedlocha A,
    3. Olsnes S,
    4. Wesche J.
    Roles of fibroblast growth factor receptors in carcinogenesis. Mol Cancer Res. 2010; 8: 1439–52.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Desai A,
    2. Adjei AA.
    FGFR signaling as a target for lung cancer therapy. J Thorac Oncol. 2016; 11: 9–20.
    OpenUrl
  6. 6.↵
    1. Perera TPS,
    2. Jovcheva E,
    3. Mevellec L,
    4. Vialard J,
    5. De Lange D,
    6. Verhulst T, et al.
    Discovery and pharmacological characterization of JNJ-42756493 (erdafitinib), a functionally selective small-molecule fgfr family inhibitor. Mol Cancer Ther. 2017; 16: 1010–20.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Tabernero J,
    2. Bahleda R,
    3. Dienstmann R,
    4. Infante JR,
    5. Mita A,
    6. Italiano A, et al.
    Phase I dose-escalation study of JNJ-42756493, an oral pan-fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors. J Clin Oncol. 2015; 33: 3401–8.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Loriot Y,
    2. Necchi A,
    3. Park SH,
    4. Garcia-Donas J,
    5. Huddart R,
    6. Burgess E, et al.
    Erdafitinib in locally advanced or metastatic urothelial carcinoma. N Engl J Med. 2019; 381: 338–48.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Bellmunt J,
    2. Theodore C,
    3. Demkov T,
    4. Komyakov B,
    5. Sengelov L,
    6. Daugaard G, et al.
    Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol. 2009; 27: 4454–61.
    OpenUrlAbstract/FREE Full Text
  10. 10.
    1. McCaffrey JA,
    2. Hilton S,
    3. Mazumdar M,
    4. Sadan S,
    5. Kelly WK,
    6. Scher HI, et al.
    Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J Clin Oncol. 1997; 15: 1853–7.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Vaughn DJ,
    2. Broome CM,
    3. Hussain M,
    4. Gutheil JC,
    5. Markowitz AB.
    Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer. J Clin Oncol. 2002; 20: 937–40.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    1. Tiseo M,
    2. Gelsomino F,
    3. Alfieri R,
    4. Cavazzoni A,
    5. Bozzetti C,
    6. De Giorgi AM, et al.
    FGFR as potential target in the treatment of squamous non small cell lung cancer. Cancer Treat Rev. 2015; 41: 527–39.
    OpenUrl
  13. 13.↵
    1. Liao RG,
    2. Jung J,
    3. Tchaicha J,
    4. Wilkerson MD,
    5. Sivachenko A,
    6. Beauchamp EM, et al.
    Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma. Cancer Res. 2013; 73: 5195–205.
    OpenUrlCrossRefPubMedWeb of Science
  14. 14.↵
    1. Shu Y,
    2. Wu X,
    3. Tong X,
    4. Wang X,
    5. Chang Z,
    6. Mao Y, et al.
    Circulating tumor DNA mutation profiling by targeted next generation sequencing provides guidance for personalized treatments in multiple cancer types. Sci Rep. 2017; 7: 583.
    OpenUrlPubMed
  15. 15.↵
    1. Yang Z,
    2. Yang N,
    3. Ou Q,
    4. Xiang Y,
    5. Jiang T,
    6. Wu X, et al.
    Investigating novel resistance mechanisms to third-generation egfr tyrosine kinase inhibitor osimertinib in non-small cell lung cancer patients. Clin Cancer Res. 2018; 24: 3097–107.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    1. Bolger AM,
    2. Lohse M,
    3. Usadel B.
    Trimmomatic: a flexible trimmer for illumina sequence data. Bioinformatics. 2014; 30: 2114–20.
    OpenUrlCrossRefPubMedWeb of Science
  17. 17.↵
    1. Koboldt DC,
    2. Zhang Q,
    3. Larson DE,
    4. Shen D,
    5. McLellan MD,
    6. Lin L, et al.
    Varscan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. 2012; 22: 568–76.
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    1. Newman AM,
    2. Bratman SV,
    3. Stehr H,
    4. Lee LJ,
    5. Liu CL,
    6. Diehn M, et al.
    Factera: a practical method for the discovery of genomic rearrangements at breakpoint resolution. Bioinformatics. 2014; 30: 3390–3.
    OpenUrlCrossRefPubMed
  19. 19.↵
    1. Chakravarty D,
    2. Gao J,
    3. Phillips S,
    4. Kundra R,
    5. Zhang H,
    6. Wang J, et al.
    Oncokb: A precision oncology knowledge base. JCO Precis Oncol. 2017; 1–16.
  20. 20.↵
    1. Costa R,
    2. Carneiro BA,
    3. Taxter T,
    4. Tavora FA,
    5. Kalyan A,
    6. Pai SA, et al.
    FGFR3-TACC3 fusion in solid tumors: mini review. Oncotarget. 2016; 7: 55924–38.
    OpenUrlPubMed
  21. 21.↵
    1. Jain P,
    2. Surrey LF,
    3. Straka J,
    4. Luo M,
    5. Lin F,
    6. Harding B, et al.
    Novel FGFR2-INA fusion identified in two low-grade mixed neuronal-glial tumors drives oncogenesis via MAPK and PI3K/mTOR pathway activation. Acta Neuropathol. 2018; 136: 167–9.
    OpenUrl
  22. 22.↵
    1. Gao L,
    2. Wang X,
    3. Tang Y,
    4. Huang S,
    5. Hu CA,
    6. Teng Y.
    FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib. J Exp Clin Cancer Res. 2017; 36: 8.
    OpenUrl
  23. 23.↵
    1. Zhang X,
    2. Kong M,
    3. Zhang Z,
    4. Xu S,
    5. Yan F,
    6. Wei L, et al.
    FGF19 genetic amplification as a potential therapeutic target in lung squamous cell carcinomas. Thorac Cancer. 2017; 8: 655–65.
    OpenUrl
  24. 24.↵
    1. Helsten T,
    2. Elkin S,
    3. Arthur E,
    4. Tomson BN,
    5. Carter J,
    6. Kurzrock R.
    The FGFR landscape in cancer: analysis of 4,853 tumors by next-generation sequencing. Clin Cancer Res. 2016; 22: 259–67.
    OpenUrlAbstract/FREE Full Text
  25. 25.↵
    1. Reck M,
    2. Kaiser R,
    3. Mellemgaard A,
    4. Douillard JY,
    5. Orlov S,
    6. Krzakowski M, et al.
    Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol. 2014; 15: 143–55.
    OpenUrlCrossRefPubMedWeb of Science
  26. 26.↵
    1. Abou-Alfa GK,
    2. Sahai V,
    3. Hollebecque A,
    4. Vaccaro G,
    5. Melisi D,
    6. Al-Rajabi R, et al.
    Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2020; 21: 671–84.
    OpenUrl
  27. 27.↵
    1. Hashemi-Sadraei N,
    2. Hanna N.
    Targeting FGFR in squamous cell carcinoma of the lung. Target Oncol. 2017; 12: 741–55.
    OpenUrl
  28. 28.↵
    1. Singleton KR,
    2. Hinz TK,
    3. Kleczko EK,
    4. Marek LA,
    5. Kwak J,
    6. Harp T, et al.
    Kinome RNAi screens reveal synergistic targeting of MTOR and FGFR1 pathways for treatment of lung cancer and HNSCC. Cancer Res. 2015; 75: 4398–406.
    OpenUrlAbstract/FREE Full Text
  29. 29.
    1. Weeden CE,
    2. Solomon B,
    3. Asselin-Labat ML.
    FGFR1 inhibition in lung squamous cell carcinoma: questions and controversies. Cell Death Discov. 2015; 1: 15049.
  30. 30.↵
    1. Wynes MW,
    2. Hinz TK,
    3. Gao D,
    4. Martini M,
    5. Marek LA,
    6. Ware KE, et al.
    FGFR1 mRNA and protein expression, not gene copy number, predict FGFR TKI sensitivity across all lung cancer histologies. Clin Cancer Res. 2014; 20: 3299–309.
    OpenUrlAbstract/FREE Full Text
  31. 31.↵
    1. Packer LM,
    2. Geng X,
    3. Bonazzi VF,
    4. Ju RJ,
    5. Mahon CE,
    6. Cummings MC, et al.
    PI3K inhibitors synergize with FGFR inhibitors to enhance antitumor responses in FGFR2(mutant) endometrial cancers. Mol Cancer Ther. 2017; 16: 637–48.
    OpenUrlAbstract/FREE Full Text
  32. 32.↵
    1. Wheler JJ,
    2. Atkins JT,
    3. Janku F,
    4. Moulder SL,
    5. Stephens PJ,
    6. Yelensky R, et al.
    Presence of both alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitors. Oncoscience. 2016; 3: 164–72.
    OpenUrl
  33. 33.↵
    1. Wang R,
    2. Wang L,
    3. Li Y,
    4. Hu H,
    5. Shen L,
    6. Shen X, et al.
    FGFR1/3 tyrosine kinase fusions define a unique molecular subtype of non-small cell lung cancer. Clin Cancer Res. 2014; 20: 4107–14.
    OpenUrlAbstract/FREE Full Text
  34. 34.↵
    1. Wu YM,
    2. Su F,
    3. Kalyana-Sundaram S,
    4. Khazanov N,
    5. Ateeq B,
    6. Cao X, et al.
    Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov. 2013; 3:636–47.
    OpenUrlAbstract/FREE Full Text
  35. 35.↵
    1. Ou SI,
    2. Horn L,
    3. Cruz M,
    4. Vafai D,
    5. Lovly CM,
    6. Spradlin A, et al.
    Emergence of FGFR3-TACC3 fusions as a potential by-pass resistance mechanism to EGFR tyrosine kinase inhibitors in EGFR mutated NSCLC patients. Lung Cancer. 2017; 111: 61–4.
    OpenUrl
  36. 36.↵
    1. Reis-Filho JS,
    2. Simpson PT,
    3. Turner NC,
    4. Lambros MB,
    5. Jones C,
    6. Mackay A, et al.
    FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas. Clin Cancer Res. 2006; 12: 6652–62.
    OpenUrlAbstract/FREE Full Text
  37. 37.↵
    1. Gao L,
    2. Lang L,
    3. Zhao X,
    4. Shay C,
    5. Shull AY,
    6. Teng Y.
    FGF19 amplification reveals an oncogenic dependency upon autocrine FGF19/FGFR4 signaling in head and neck squamous cell carcinoma. Oncogene. 2019; 38: 2394–404.
    OpenUrl
PreviousNext
Back to top

In this issue

Cancer Biology and Medicine: 18 (2)
Cancer Biology & Medicine
Vol. 18, Issue 2
1 May 2021
  • Table of Contents
  • Index by author
Print
Download PDF
Email Article

Thank you for your interest in spreading the word on Cancer Biology & Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Targeting FGFR in non-small cell lung cancer: implications from the landscape of clinically actionable aberrations of FGFR kinases
(Your Name) has sent you a message from Cancer Biology & Medicine
(Your Name) thought you would like to see the Cancer Biology & Medicine web site.
Citation Tools
Targeting FGFR in non-small cell lung cancer: implications from the landscape of clinically actionable aberrations of FGFR kinases
Zhen Zhou, Zichuan Liu, Qiuxiang Ou, Xue Wu, Xiaonan Wang, Yang Shao, Hongyan Liu, Yu Yang
Cancer Biology & Medicine May 2021, 18 (2) 490-501; DOI: 10.20892/j.issn.2095-3941.2020.0120

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Targeting FGFR in non-small cell lung cancer: implications from the landscape of clinically actionable aberrations of FGFR kinases
Zhen Zhou, Zichuan Liu, Qiuxiang Ou, Xue Wu, Xiaonan Wang, Yang Shao, Hongyan Liu, Yu Yang
Cancer Biology & Medicine May 2021, 18 (2) 490-501; DOI: 10.20892/j.issn.2095-3941.2020.0120
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and methods
    • Results
    • Discussion
    • Conclusions
    • Supporting Information
    • Grant support
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • References
  • PDF

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • A novel biguanide-derivative promotes NEDD4-mediated FGFR1 ubiquitination through BMI1 to overcome osimertinib resistance in NSCLC
  • Google Scholar

More in this TOC Section

  • Effective anti-PD-1 therapy reduces neutrophil infiltration via T cell–macrophage chemokine axis in hepatocellular carcinoma
  • Single-cell and spatial transcriptome analyses reveal tumor immunometabolism in lymph node metastasis of lung cancer
  • An integrated CT/MRI diagnostic system for pancreatic cystic lesions that supports pathological classification and risk stratification
Show more Original Article

Similar Articles

Keywords

  • FGFR
  • oncogenic mutation
  • fusion
  • gene amplification
  • targeted therapy

Navigate

  • Home
  • Current Issue

More Information

  • About CBM
  • About CACA
  • About TMUCIH
  • Editorial Board
  • Subscription

For Authors

  • Instructions for authors
  • Journal Policies
  • Submit a Manuscript

Journal Services

  • Email Alerts
  • Facebook
  • RSS Feeds
  • Twitter

 

© 2026 Cancer Biology & Medicine

Powered by HighWire